Illinois Governor JB Pritzker signed into law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.
JB Pritzker
The fight against pharmacy benefit managers (PBMs) has gained more ground this month as Illinois Governor JB Pritzker signed HB 3631 into law. The legislation, led by Democratic Representatives Hoan Huynh and Mike Simmons prohibits PBMs from retaliating against pharmacists who disclose information through the course of government proceedings, if that pharmacist had “reasonable cause” to believe that the information is evidence of a violation of a state or federal law, rule, or regulation.1
Pritzker signed the bill on August 4, 2023.
Pharmacists who speak out against PBMs have experienced retaliatory measures, including an “exponential increase in audits, refusal to access future contracts, and removal from preferred provider networks,” according to a National Community Pharmacists Association (NCPA) press release.1
NCPA and the Illinois Pharmacists Association have applauded the bill. “PBMs…have been weaponizing contracting and auditing tactics to essentially force pharmacists into silence,” said Garth Reynolds, RPh, Illinois Pharmacists Association executive director, in a press release.1 “With HB 3631, we can more freely share with government representatives how PBM policies harm pharmacy practice and our patients.”
Joel Kurzman, director of state government affairs at the NCPA, also praised the legislation. “For a marketplace to be free and healthy, there must be competition and transparency,” he said. “PBM-insurers are fighting against both, even as policymakers at all levels of government look to crack down on business practices that stifle patient choice and disadvantage independent pharmacies.”1
“This legislation is a great step forward in Illinois,” he continued. “Further PBM reforms and aggressive enforcement of policies like this one will be crucial if patients and taxpayers are to see the difference.”
Pritzker has previously enacted legislation aimed at managing PBMs. In 2019, he signed HB 465, which created Illinois’ first comprehensive regulatory framework for PBMs. Per the legislation, insurers are now required to apply third-party payments, discounts, vouchers, and copay cards to a deductible, copay, or out-of-pocket maximum associated with health insurance; prevent gag clauses limiting pharmacists from advising patients about available lower-cost alternatives or cash pay options; and provide greater transparency around the pricing and reimbursement models used by PBMs by requiring state agencies to approve contracts impacting Medicaid.2
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More